Loading
EPHA5 (Ephrin type-A receptor 5) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and Neuroendocrine tumours.
Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signalling into neighboring cells. The signalling pathway downstream of the receptor is referred to as forward signalling while the signalling pathway downstream of the ephrin ligand is referred to as reverse signalling. Among GPI-anchored ephrin-A ligands, EFNA5 most probably constitutes the cognate/functional ligand for EPHA5.
Open Targets scores its association with cancer at 0.65 (direct and indirect evidence; datatypes literature 0.96, genetic association 0.39, clinical 0.93).
In plain words · EPHA5 (Ephrin type-A receptor 5) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and Neuroendocrine tumours.
EPHA5 (Ephrin type-A receptor 5) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and Neuroendocrine tumours.
Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signalling into neighboring cells.
No product in this corpus aims at EPHA5 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA EPHA5: RNA tissue enriched (brain 11 nTPM); no normal tissue stained high. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Thyroid cancer, Neuroendocrine tumours); Open Targets associates it with 1 specific cancer type at or above 0.5 (medullary thyroid gland carcinoma). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas EPHA5 tissue; Open Targets ENSG00000145242 associations
First described 1995. Earliest sequence paper UniProt cites for the protein: Fox G.M. et al, Oncogene, 1995, "cDNA cloning and tissue distribution of five human EPH-like receptor protein-tyrosine kinases". Source.
Sources: HGNC HGNC:3389 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P54756 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000145242 (association with cancer (MONDO_0004992) 0.65; per-cancer scores at or above 0.5: thyroid cancer 0.57, neuroendocrine neoplasm 0.54 (GraphQL API, CC0))
Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signalling into neighboring cells. The signalling pathway downstream of the receptor is referred to as forward signalling while the signalling pathway downstream of the ephrin ligand is referred to as reverse signalling. Among GPI-anchored ephrin-A ligands, EFNA5 most probably constitutes the cognate/functional ligand for EPHA5. Functions as an axon guidance molecule during development and may be involved in the development of the retinotectal, entorhino-hippocampal and hippocamposeptal pathways. Together with EFNA5 plays also a role in synaptic plasticity in adult brain through regulation of synaptogenesis. In addition to its function in the nervous system, the interaction of EPHA5 with EFNA5 mediates communication between pancreatic islet cells to regulate glucose-stimulated insulin secretion. Location: Cell membrane; Cell projection, axon; Cell projection, dendrite (UniProt). Locus 4q13.1-q13.2 (HGNC).
RNA: tissue enriched (brain 11 nTPM), detected in some normal tissues.
No normal tissue stained high.
RNA cancer enhanced: Glioblastoma Multiforme 2 pTPM, Prostate Adenocarcinoma 1 pTPM.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"EPHA5" OR ABSTRACT:"EPHA5" OR TITLE:"EPH receptor A5" OR ABSTRACT:"EPH receptor A5" OR TITLE:"Ephrin type-A receptor 5" OR ABSTRACT:"Ephrin type-A receptor 5" OR TITLE:"Hek7" OR ABSTRACT:"Hek7" OR TITLE:"TYRO4" OR ABSTRACT:"TYRO4" OR TITLE:"CEK7" OR ABSTRACT:"CEK7") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EPHA5, not a curated reading list.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Open Targets Platform.